Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth.
PISCATAWAY, N.J., March 12, 2025 /PRNewswire/ — GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacturing reported its financial results for the full year ended on December 31, 2024.
FY 2024 Result Highlights
Deconsolidation of cell therapy business resulted in a gain of $3.2 Billion.
Revenue from the continuing operations (sans cell therapy business) was $594.5 Million compared to $560.5 Million for the year ended December 31, 2023 (the “Prior Period”).
Profit of the Group has increased to approximately $2.9 Billion, whilst the loss of the Group …
Leave a Reply
You must be logged in to post a comment.